TWThomas C. Wascher

Thomas C. Wascher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas C. Wascher has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nephropathie und Diabetes mellitus

    by Alexander Rosenkranz, Thomas C. Wascher, Martin Clodi, Heinz Drexel, Kathrin Eller, Peter Fasching, Alexandra Kautzky-Willer, Reinhard Kramar, Bernhard Ludvik, Gert Mayer, et al.

  • Blutzuckerselbstkontrolle

    by Thomas C. Wascher

    Blutzuckerselbstkontrolle trägt zum integrierten Management des Diabetes Mellitus bei. Sie sollte für alle Patienten mit Typ-1 und Typ-2 Diabetes zur Verfügung stehen. Die Blutzuckerselbstkontrolle erhöht die Patientensicherheit, die Lebensqualität und verbessert die Blutzuckerkontrolle. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz der Blutzuckerselbstkontrolle dar. Self monitoring of blood glucose contributes to the integrated management of diabetes mellitus. It, thus, should be available for all patients with diabetes mellitus type-1 and type-2. Self monitoring of blood glucose improves patients safety, quality of life and glucose control. The current article represents the recommendations of the Austrian Diabetes Association for the use of blood glucose self monitoring according to current scientific evidence.


  • Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2

    by Thomas C. Wascher, Bernhard Paulweber, Hermann Toplak, Christoph Saely, Heinz Drexel

    Hyper- and Dyslipidemia contribute to cardiovascular morbidity and mortality in diabetic patients. Pharmacological therapy with statins has convincingly shown to reduce cardiovascular risk in diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in diabetic patients according to current scientific evidence. Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass durch die medikamentöse Therapie mit Statinen das kardiovaskuläre Risiko von Diabetikern senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der österreichischen Diabetesgesellschaft zum Einsatz lipidsenkender Medikamente dar.


  • Insulin Resistance as a Risk Factor for Carotid Atherosclerosis

    by Harald Sourij, Isabella Schmoelzer, Peter Dittrich, Bernhard Paulweber, Bernhard Iglseder, Thomas C. Wascher

    Background and Purpose— The independent contribution of insulin resistance to atherosclerosis is still under debate. We compared associations of 2 different indices of insulin resistance, the Homeostasis Model Assessment (HOMA) index and kITT from a short insulin tolerance test with carotid atherosclerosis. Methods— A total of 1771 middle-aged white patients were investigated. Intima media thickness (IMT) and extent of carotid atherosclerosis were quantified by ultrasound. HOMA was calculated and an insulin tolerance test was performed. Results— HOMA and kITT were significant predictors for average carotid IMT ( P avg ( P =0.02), whereas kITT failed to do so. HOMA and kITT were also predictive ( P =0.004 and P =0.024) for carotid plaques and extent of carotid atherosclerosis ( P Conclusions— Our results provide evidence that HOMA rather than kITT is associated with carotid atherosclerosis and that the association is largely explained by the clustered expression of the components of the metabolic syndrome.


  • Open Access

    The MHC2TA-168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients

    by Babak Yazdani-Biuki, Kerstin Brickmann, Klaus Wohlfahrt, Thomas Mueller, Winfried März, Wilfried Renner, Manuela Gutjahr, Uwe Langsenlehner, Peter Krippl, Thomas C Wascher, et al.

    An association between susceptibility to rheumatoid arthritis (RA) and a common -168A>G polymorphism in the MHC2TA gene with differential major histocompatibility complex (MHC) II molecule expression was recently reported in a Swedish population. The objective of the present study was to replicate this finding by examining the -168A>G polymorphism in an Austrian case–control study. Three hundred and sixty-two unrelated RA cases and 351 sex-matched and age-matched controls as well as 1,709 Austrian healthy individuals were genotyped. All participants were from the same ethnic background. Genotyping was performed using 5' allelic discrimination assays. The association between susceptibility to RA and the -168A>G single nucleotide polymorphism was examined by chi-square test. Comparison was made assuming a dominant effect (AG + GG genotypes versus AA genotype). In contrast to the primary report, the frequency of MHC2TA -168G allele carriers was not significantly different between patients and controls in the Austrian cohort. The homozygous MHC2TA -168 GG genotype was more frequent in matched controls than in Austrian RA patients. There was no association between the presence of RA-specific autoantibodies and the MHC2TA -168 GG genotype. In this cohort of Austrian patients, no association between the MHC2TA polymorphism and RA was found.


  • Open Access

    Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance

    by Isabella Schmoelzer, Thomas C Wascher

    Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular risk. The pathophysiological mechanisms linking post-challenge hyperglycemia to accelerated atherosclerosis, however remain to be elucidated. Methods: A prospective, open, randomised, cross-over study was performed to investigate the effect of 2 mg repaglinide on hyperglycemia and endothelial function during an oral glucose tolerance test (75 g glucose) in 12 subjects with diagnosed IGT. Blood samples for determination of plasma glucose were drawn fasting, 1 and 2 hours after glucose ingestion. Endothelial function was assessed by measuring flow-mediated dilatation (FMD) of the brachial artery with high-resolution ultrasound. Results: Administration of repaglinide resulted in a significant reduction of plasma glucose at 2 hours (172.8+/-48.4 vs. 138.3+/-41.2 mg/dl; p < 0.001). The flow-mediated dilatation (FMD) 2 hours after the glucose-load was significantly reduced in comparison to fasting in the control group (6.21+/-2.69 vs. 7.98+/-2.24 %; p = 0.028), whereas after theadministration of repaglinide the FMD was not significantly different to fasting values (7.24+/-2.57 vs. 8.18+/-2.93 %; p = n.s.). Linear and logistic regression analysis revealed that only the change of glucose was significantly correlated to the change of FMD observed (p < 0.001). Regression analysis after grouping for treatment and time confirmed the strong negative association of the changes of plasma glucose and FMD and indicate that the effect of repaglinide observed is based on the reduction glycemia. Conclusion: In subjects with IGT, the endothelial dysfunction observed after a glucose challenge is related to the extent of hyperglycemia. Reduction of hyperglycemia by repaglinide reduces endothelial dysfunction in a glucose dependent manner.


  • Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance

    by T. C. Wascher, I. Schmoelzer, A. Wiegratz, M. Stuehlinger, D. Mueller‐Wieland, J. Kotzka, M. Enderle

    Objectives  To investigate whether selective reduction of postchallenge hyperglycaemia influences acute endothelial dysfunction, a very early manifestation of vascular disease, in patients with impaired glucose tolerance.Methods  In a randomized, double‐blind, placebo‐controlled, cross‐over study the acute effect of 200‐mg acarbose was investigated in 28 subjects with diagnosed impaired glucose tolerance. Flow‐mediated dilation (FMD) of the brachial artery was determined as a measure of endothelial function before and 2 and 3 h after ingestion of 100‐g saccharose. Asymmetrical dimethylarginine (ADMA) was measured by high‐performance liquid chromatography.Results  A negative correlation was observed between the changes of glucose and FMD (r = 0·416, P = 0·0018) 2 h after ingestion of saccharose. At 3 h, neither blood glucose nor FMD were different from baseline. Changes of both blood glucose (P = 0·0007) and FMD (P = 0·046) were significantly lower after administration of acarbose. Subgroup analysis revealed that the effect of acarbose was restricted to those subjects with an increase of blood glucose above the median increase of glycaemia. No changes of plasma ADMA were observed.Conclusions  Our data clearly demonstrate that the postchallenge alteration of vascular function in patients with impaired glucose tolerance is caused by the acute elevation of glycaemia but not mediated by ADMA.


  • Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients

    by Thomas C. Wascher, Ursula Boes

    Summary: Sulphonylureas (SUs) act by inhibition of β‐cell KATP channels after binding to the sulphonylurea receptor SUR1. KATP channels are also expressed in cardiac and vascular myocytes coupled to SUR2A and SUR2B involved into adaptations of vascular tone and myocardial contractility. Different influence of SUs on vascular function is based on different binding to the SUR family. Few data on the effect of different SUs, used in patients in therapeutic doses, on vascular function are currently available. We investigated possible effects of acute and chronic treatment with glibenclamide and gliclazide on forearm postischaemic reactive hyperaemia (RH) in type 2 diabetic patients. To that purpose a double‐blind, randomized, cross‐over study with gliclazide (80 mg, b.i.d.) and glibenclamide (5 mg, b.i.d.) was performed in 15 type 2 diabetic patients. Forearm vascular reactivity was measured after 5 min of ischaemia by plethysmography before and after 4 weeks treatment. After acute administration of gliclazide (80 mg) or glibenclamide (5 mg) RH was not influenced. After 4 weeks of treatment, no influence of either drug was seen in the steady state before dosing. After dosing glibenclamide induced a significant (P = 0·004) reduction of RH from 26·4 ± 6·9 to 21·9 ± 7·6 ml min−1/100 ml after 4 h. Gliclazide, conversely, did not induce a reduction of RH (23·9 ± 6·0 to 23·3 ± 6·6 ml min−1/100 ml). No influence of HbA1c or actual glycaemia on RH was observed. Our results indicate that in chronically treated patients with type 2 diabetes ingestion of glibenclamide but not gliclazide results in sustained reduction of postischaemic RH. This difference is most probably based on different SUR binding.


  • Hemochromatosis gene (HFE) polymorphisms are not associated with peripheral arterial disease

    by Peter Krippl, Robert Gasser, Thomas C. Wascher, Bernhard Paulweber, Ernst Pilger, Wilfried Renner, Herwig Köppel